# Rules of Department of Social Services
## Division 70—MO HealthNet Division
### Chapter 20—Pharmacy Program

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>13 CSR 70-20.010 Participating Drug Vendors (Rescinded September 30, 2018)</td>
<td>3</td>
</tr>
<tr>
<td>13 CSR 70-20.030 Drugs Covered by Medicaid</td>
<td>3</td>
</tr>
<tr>
<td>13 CSR 70-20.031 List of Excludable Drugs for Which Prior Authorization Is Required</td>
<td>4</td>
</tr>
<tr>
<td>13 CSR 70-20.032 List of Excludable Drugs Excluded From Coverage Under the MO HealthNet Pharmacy Program</td>
<td>4</td>
</tr>
<tr>
<td>13 CSR 70-20.033 Medicaid Program Coverage of Investigational Drugs Used in the Treatment of Acquired Immunodeficiency Syndrome (AIDS) (Rescinded September 30, 2018)</td>
<td>4</td>
</tr>
<tr>
<td>13 CSR 70-20.034 List of Non-Excludable Drugs for Which Prior Authorization Is Required</td>
<td>5</td>
</tr>
<tr>
<td>13 CSR 70-20.040 Five Prescription Limit Per Month Per Recipient</td>
<td>5</td>
</tr>
<tr>
<td>13 CSR 70-20.045 Thirty-One Day Supply Maximum Restriction on Pharmacy Services Reimbursed by the MO HealthNet Division</td>
<td>6</td>
</tr>
<tr>
<td>13 CSR 70-20.050 Return of Drugs</td>
<td>7</td>
</tr>
<tr>
<td>13 CSR 70-20.060 Professional Dispensing Fee</td>
<td>7</td>
</tr>
<tr>
<td>13 CSR 70-20.070 Computer-Generated Drug Pricing Tape and Drug Reimbursement Methodology</td>
<td>8</td>
</tr>
<tr>
<td>13 CSR 70-20.071 Multiple Source Drugs for Which There Exists a Federal Upper Limit on Reimbursement (Rescinded September 30, 2018)</td>
<td>8</td>
</tr>
<tr>
<td>13 CSR 70-20.080 Labeling of Medicaid Prescriptions (Rescinded December 9, 1993)</td>
<td>8</td>
</tr>
<tr>
<td>13 CSR 70-20.100 Missouri Nonsteroidal Anti-Inflammatory Drug List (Rescinded September 30, 1991)</td>
<td>8</td>
</tr>
<tr>
<td>13 CSR 70-20.110 Medicaid Program Coverage of Approved Drugs for Treatment of Acquired Immunodeficiency Syndrome (AIDS) (Rescinded September 30, 1991)</td>
<td>8</td>
</tr>
<tr>
<td>13 CSR 70-20.120 Medicaid Program Coverage of Anti-Ulcer Preparations (Rescinded June 29, 1989)</td>
<td>9</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>13 CSR 70-20.200</td>
<td>Drug Prior Authorization Process</td>
</tr>
<tr>
<td>13 CSR 70-20.250</td>
<td>Prior Authorization of New Drug Entities or New Drug Dosage Form</td>
</tr>
<tr>
<td>13 CSR 70-20.300</td>
<td>Retrospective Drug Use Review Process</td>
</tr>
<tr>
<td>13 CSR 70-20.310</td>
<td>Prospective Drug Use Review Process and Patient Counseling</td>
</tr>
<tr>
<td>13 CSR 70-20.320</td>
<td>Pharmacy Reimbursement Allowance</td>
</tr>
<tr>
<td>13 CSR 70-20.330</td>
<td>Medication Therapy Management (MTM) Program</td>
</tr>
<tr>
<td>13 CSR 70-20.340</td>
<td>National Drug Code Requirement</td>
</tr>
</tbody>
</table>
34 Title 13—DEPARTMENT OF SOCIAL SERVICES
Division 70—MO HealthNet Division
Chapter 20—Pharmacy Program

13 CSR 70-20.010 Participating Drug Vendors
(Rescinded September 30, 2018)

AUTHORITY: section 207.020, RSMo 1986.

13 CSR 70-20.030 Drugs Covered by Medicaid

PURPOSE: This rule implements recent changes in drug coverage as mandated by federal Health Care Financing Administration.

(1) Limiting Definition—As defined in the Social Security Act, section 1927(k)(3), the term covered outpatient drug does not include any drug, biological product, or insulin provided as part of, or as incident to and in the same setting as any of the following (and for which payment may be made under this title as part of payment for the following and not as direct reimbursement for the drug):

“A (A) Inpatient hospital services.
“B (B) Hospice services.
“C (C) Dental services, except that drugs for which the state plan authorized direct reimbursement to the dispensing dentist are covered outpatient drugs.
“D (D) Physicians’ services.
“E (E) Outpatient hospital services.
“F (F) Nursing facility services and services provided by an intermediate care facility for the mentally retarded.
“G (G) Other laboratory and x-ray services.
“H (H) Renal dialysis.

Such term also does not include any such drug or product for which a National Drug Code number is not required by the Food and Drug Administration or a drug or biological used for a medical indication which is not a medically accepted indication.”

(2) Participating Manufacturers—The Missouri Division of Medical Services identifies those manufacturers whose products are reimbursable along with effective dates of coverage, based on date of service, corresponding to effective dates of their participation under the national rebate contract. All products marketed by participating manufacturers are reimbursable, with the following exceptions: those products identified as Drug Efficacy Study Implementation (DESI) drugs by the federal Food and Drug Administration (FDA); products considered by the federal FDA to be similar, identical or related to a DESI product; products identified in 13 CSR 70-20.031 and 13 CSR 70-20.032; and products not meeting the definition of drug in sections 505, 506 and 507 of the federal Food, Drug and Cosmetic Act.

(3) According to the federal Social Security Act, section 1927(a)(1) in order for federal financial participation to be available for covered outpatient drugs of a manufacturer, the manufacturer must have entered into and have in effect a rebate agreement with the secretary of the federal Department of Health and Human Services. States are periodically notified by the federal Health Care Financing Administration of manufacturers that have entered into as well as terminated rebate agreements with the secretary of the federal Department of Health and Human Services. The Missouri Medicaid Pharmacy Manual and updating bulletins shall provide the detailed listing of manufacturers that have in effect a rebate agreement with the federal Department of Health and Human Services.

13 CSR 70-20.031 List of Excludable Drugs for Which Prior Authorization Is Required

PURPOSE: This rule establishes a listing of excludable drugs and categories of drugs for which prior authorization is required in order for them to be reimbursable under the MO HealthNet Pharmacy Program.

PUBLISHER’S NOTE: The secretary of state has determined that the publication of the entire text of the material which is incorporated by reference as a portion of this rule would be unduly cumbersome or expensive. This material as incorporated by reference in this rule shall be maintained by the agency at its headquarters and shall be made available to the public for inspection and copying at no more than the actual cost of reproduction. This note applies only to the reference material. The entire text of the rule is printed here.

(1) Permissible Exclusions—As specified in the Social Security Act, Section 1927(d)(1)(B), states may exclude or otherwise restrict coverage of certain covered outpatient drugs. Section 1927(d)(2) of the Social Security Act provides a listing of the categories of drugs that are permissible for exclusion. Drugs included on this list may be excluded from coverage entirely or restricted by diagnosis as determined by the state.

(2) As specified in Section 1927(d)(1) of the Social Security Act, states may subject to prior authorization any covered outpatient drug. Any such prior authorization program shall comply with the requirements of Section 1927(d)(5) of the Social Security Act.

(3) List of drugs or categories of excludable drugs which are restricted to require prior authorization for certain specified indications shall be made available through the Department of Social Services, MO HealthNet Division website at dss.mo.gov/mhd, provider bulletins, and updates to the provider manual which are incorporated by reference and made a part of this rule as published by the Department of Social Services, MO HealthNet Division, 615 Howerton Court, Jefferson City, MO 65109, at its website, October 15, 2013. This rule does not incorporate any subsequent amendments or additions. The division reserves the right to affect changes in the list of excludable drugs for which prior authorization is required by amending this rule.


13 CSR 70-20.032 List of Excludable Drugs Excluded From Coverage Under the MO HealthNet Pharmacy Program

PURPOSE: This rule establishes a listing of excludable drugs or categories for which reimbursement is not available through the MO HealthNet Pharmacy Program.

PUBLISHER’S NOTE: The secretary of state has determined that the publication of the entire text of the material which is incorporated by reference as a portion of this rule would be unduly cumbersome or expensive. This material as incorporated by reference in this rule shall be maintained by the agency at its headquarters and shall be made available to the public for inspection and copying at no more than the actual cost of reproduction. This note applies only to the reference material. The entire text of the rule is printed here.

(1) Permissible Exclusions—As specified in the Social Security Act, Section 1927(d)(1)(B), states may exclude or otherwise restrict coverage of certain covered outpatient drugs. Section 1927(d)(2) of the Social Security Act provides a listing of the categories of drugs that are permissible for exclusion. Drugs included on this list may be excluded from coverage entirely or restricted by diagnosis as determined by the state.

(2) As specified in Section 1927(d)(1) of the Social Security Act, states may subject to prior authorization any covered outpatient drug. Any such prior authorization program shall comply with the requirements of Section 1927(d)(5) of the Social Security Act.

(3) List of drugs or categories of excludable drugs which are restricted to require prior authorization for certain specified indications shall be made available through the Department of Social Services, MO HealthNet Division website at dss.mo.gov/mhd, provider bulletins, and updates to the provider manual which are incorporated by reference and made a part of this rule as published by the Department of Social Services, MO HealthNet Division, 615 Howerton Court, Jefferson City, MO 65109, at its website, October 15, 2013. This rule does not incorporate any subsequent amendments or additions. The division reserves the right to affect changes in the list of excludable drugs for which prior authorization is required by amending this rule.


13 CSR 70-20.033 Medicaid Program Coverage of Investigational Drugs Used in the Treatment of Acquired Immunodeficiency Syndrome (AIDS) (Rescinded September 30, 2018)
13 CSR 70-20.034 List of Non-Excludable Drugs for Which Prior Authorization Is Required

PURPOSE: This rule establishes a listing of non-excludable drugs and categories of drugs for which prior authorization is required in order for them to be reimbursable under the MO HealthNet Pharmacy Program.

PUBLISHER’S NOTE: The secretary of state has determined that the publication of the entire text of the material which is incorporated by reference as a portion of this rule would be unduly cumbersome or expensive. This material as incorporated by reference in this rule shall be maintained by the agency at its headquarters and shall be made available to the public for inspection and copying at no more than the actual cost of reproduction. This note applies only to the reference material. The entire text of the rule is printed here.

(1) As specified in section 1927(d)(1) of the Social Security Act, states may subject to prior authorization any covered outpatient drug. Any such prior authorization program shall comply with the requirements of section 1927(d)(5) of the Social Security Act.

(2) List of drugs or categories of drugs which are restricted to require prior authorization for certain specified indications shall be made available through the Department of Social Services, MO HealthNet Division website at www.dss.mo.gov/mhd, provider bulletins, and updates to the provider manual which are incorporated by reference in this rule shall be maintained by the agency at its headquarters and shall be made available to the public for inspection and copying at no more than the actual cost of reproduction. This note applies only to the reference material. The entire text of the rule is printed here.

13 CSR 70-20.040 Five Prescription Limit Per Month Per Recipient

PURPOSE: This rule imposes a limitation on the number of prescriptions which may be covered services within a specified time period for each recipient.

(1) The number of prescriptions which may be filled or refilled will be limited to five (5) per recipient during any one (1) period of eligibility which does not exceed the normal monthly eligibility span for the recipient’s assistance category involved.

(A) The only allowable exception to the five (5)-prescription limitation will be for certain specified drugs which are commonly prescribed for long-term chronic medical conditions and for prior authorized drugs.

(B) These listed drugs shall be considered to be used for the treatment of long-term chronic medical conditions and shall therefore be exempted from the prescription limitation.

- Acetohexamide
- Acetaminophen
- Albuterol
- Amodorin HCl Tablets
- Aminophylline
- Anhydrous Calcium Iodide and Isoproterenol Sulfate Syrup
- Atenolol and Chlorthalidone Tablets
- Beclomethasone Dipropionate
- Beclomethasone Nasal Spray
- Benfotiamine Tablets
- Benzotropine Mesylate
- Betaxolol HCl Ophthalmic Solution
- Bethanechol Chloride
- Biperiden Tablets
- Botulotyl Mesylate
- Butametaine Tablets
- Captopril and Hydrochlorothiazide Tablets
- Captoril Tablets
- Carbamazepine
- Carbidopa and Levodopa
- Chlorthalidone
- Chlorpropamide Tablets
- Clonidine HCl
- Clomazepam
- Colestipol HCl
- Cromolyn Sodium
- Demecarium Bromide Ophthalmic Solution
- Deserpidine and Methylclothezide
- Dexamethasone Sodium Phosphate
- Dicumarol Tablets
- Diltiazem HCl
- Diltiazem HCl Sustained Release Capsules
- Dipivefrin HCl Ophthalmic Solution
- Dipyriramol
- Disopyramide
- Disopyramide Sustained Release Capsules
- Dyphylline
- Dyphylline and Guaifenesin
- Esclergothesiphate Iodide Ophthalmic Solution
- Enalapril Maleate
- Enalapril Maleate and Hydrochlorothiazide
- Enacainide HCl
- Ephephrine Sulfate Capsules
- Ephedrine Sulfate
- Ephedrine Sulfate and Guaifenesin
- Epinephrine Ophthalmic Solution
- Ergoloid Mesylates Sibungual
- Ethacrynic Acid
- Ethosuximide
- Flecaïne
- Flunisolide Nasal Spray
- Flunisolide Oral Inhaler
- Furosemide
- Genfibrizil
- Glibizide
- Glyburide
- Guaiifenesin and Oxtirphylline Tablets
- Guaiifenesin and Phenylpropanolamine HCl Sustained Release Tablets
- Guaiifenesin and Theophylline Sodium Glycinate Tablets
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Formulations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guainfenesin and Pseudoephedrine HCl</td>
<td>Sustained Release Tablets</td>
</tr>
<tr>
<td>Guainfenesin and Theophylline Capsules</td>
<td></td>
</tr>
<tr>
<td>Guainfenesin and Theophylline Tablets</td>
<td></td>
</tr>
<tr>
<td>Guanabenz Acetate Tablets</td>
<td></td>
</tr>
<tr>
<td>Guandrel Sulfate Tablets</td>
<td></td>
</tr>
<tr>
<td>Guanethidine Monosulfate and Hydrochlorothiazide Tablets</td>
<td></td>
</tr>
<tr>
<td>Guanethidine Monosulfate Tablets</td>
<td></td>
</tr>
<tr>
<td>Guanfacine HCl</td>
<td></td>
</tr>
<tr>
<td>Hydralazine</td>
<td></td>
</tr>
<tr>
<td>Hydralazine and Hydrochlorothiazide</td>
<td></td>
</tr>
<tr>
<td>Hydralazine, Hydrochlorothiazide and Reserpine</td>
<td></td>
</tr>
<tr>
<td>Hydrochlorothiazide and Lisinopril</td>
<td></td>
</tr>
<tr>
<td>Hydrochlorothiazide and Methylpap-dopa Tablets</td>
<td></td>
</tr>
<tr>
<td>Hydrochlorothiazide and Metoprolol Tartrate</td>
<td></td>
</tr>
<tr>
<td>Hydrochlorothiazide and Spironolactone Tablets</td>
<td></td>
</tr>
<tr>
<td>Hydrochlorothiazide and Timolol</td>
<td></td>
</tr>
<tr>
<td>Hydrochlorothiazide and Triamterene</td>
<td></td>
</tr>
<tr>
<td>Hydrochlorothiazide Tablets</td>
<td></td>
</tr>
<tr>
<td>Hydrochlorothiazide with Labetalol</td>
<td></td>
</tr>
<tr>
<td>Hydroflumethiazide and Reserpine</td>
<td></td>
</tr>
<tr>
<td>Indapamide Tablets</td>
<td></td>
</tr>
<tr>
<td>Indomethacin Suppositories</td>
<td></td>
</tr>
<tr>
<td>Insulin</td>
<td></td>
</tr>
<tr>
<td>Intravenous Fluids</td>
<td></td>
</tr>
<tr>
<td>Dextrose 25%, Sodium Chloride 0.45%</td>
<td></td>
</tr>
<tr>
<td>Dextrose 5%</td>
<td></td>
</tr>
<tr>
<td>Dextrose 5%, Lactated Ringer’s</td>
<td></td>
</tr>
<tr>
<td>Dextrose 5%, Sodium Chloride 0.225%</td>
<td></td>
</tr>
<tr>
<td>Dextrose 5%, Sodium Chloride 0.3%</td>
<td></td>
</tr>
<tr>
<td>Dextrose 5%, Sodium Chloride 0.45%</td>
<td></td>
</tr>
<tr>
<td>Dextrose 5%, Sodium Chloride 0.9%</td>
<td></td>
</tr>
<tr>
<td>Lactated Ringer’s Sodium Chloride 0.45%</td>
<td></td>
</tr>
<tr>
<td>Lactated Ringer’s Sodium Chloride 0.9%</td>
<td></td>
</tr>
<tr>
<td>Ipatropium Bromide</td>
<td></td>
</tr>
<tr>
<td>Isoetharine HCl</td>
<td></td>
</tr>
<tr>
<td>Isoflurophate Ophthalmic</td>
<td></td>
</tr>
<tr>
<td>Isoproterenol</td>
<td></td>
</tr>
<tr>
<td>Isoproterenol and Phenylephrine</td>
<td>Bitartrate Oral Inhaler</td>
</tr>
<tr>
<td>Isosorbide Dinitrate</td>
<td></td>
</tr>
<tr>
<td>Labetalol</td>
<td></td>
</tr>
<tr>
<td>Levobunolol HCl Ophthalmic Solution</td>
<td></td>
</tr>
<tr>
<td>Levodopa</td>
<td></td>
</tr>
<tr>
<td>Levothyrinone Sodium</td>
<td></td>
</tr>
<tr>
<td>Lisinopril</td>
<td></td>
</tr>
<tr>
<td>Lovastatin</td>
<td></td>
</tr>
<tr>
<td>Mecamylamine HCl</td>
<td></td>
</tr>
<tr>
<td>Metaproterenol Sulfate</td>
<td></td>
</tr>
<tr>
<td>Methazolamide Tablets</td>
<td></td>
</tr>
<tr>
<td>Methcylothiazide</td>
<td></td>
</tr>
<tr>
<td>Metyldopa</td>
<td></td>
</tr>
<tr>
<td>Metolazone</td>
<td></td>
</tr>
<tr>
<td>Metoprolol Tartrate</td>
<td></td>
</tr>
<tr>
<td>Metoxorine</td>
<td></td>
</tr>
<tr>
<td>Mexiletine HCl</td>
<td></td>
</tr>
<tr>
<td>Nadolol Tablets</td>
<td></td>
</tr>
<tr>
<td>Niacin Tablets</td>
<td></td>
</tr>
<tr>
<td>Nicardipine HCl</td>
<td></td>
</tr>
<tr>
<td>Nifedipine Capsules</td>
<td></td>
</tr>
<tr>
<td>Nifedipine Controlled Release Tablets</td>
<td></td>
</tr>
<tr>
<td>Nitroglycerin Spray</td>
<td></td>
</tr>
<tr>
<td>Nitroglycerin Sublingual Tablets</td>
<td></td>
</tr>
<tr>
<td>Nitroglycerin Sustained Release Capsules</td>
<td></td>
</tr>
<tr>
<td>Nitroglycerin Topical Ointment</td>
<td></td>
</tr>
<tr>
<td>Nitroglycerin Transdermal Systems</td>
<td></td>
</tr>
<tr>
<td>Oxtipryline</td>
<td></td>
</tr>
<tr>
<td>Papaverine HCl Sustained Release 150 mg.</td>
<td></td>
</tr>
<tr>
<td>Pentoxifylline</td>
<td></td>
</tr>
<tr>
<td>Phenobarbital</td>
<td></td>
</tr>
<tr>
<td>Phenyltoin</td>
<td></td>
</tr>
<tr>
<td>Pilocarpine HCl Ophthalmic Solution</td>
<td></td>
</tr>
<tr>
<td>Pindolol</td>
<td></td>
</tr>
<tr>
<td>Pirbuterol Acetate</td>
<td></td>
</tr>
<tr>
<td>Polytiazide</td>
<td></td>
</tr>
<tr>
<td>Potassium Chloride Capsules</td>
<td></td>
</tr>
<tr>
<td>Potassium Chloride 10% Liquid</td>
<td></td>
</tr>
<tr>
<td>Potassium Chloride 20% Liquid</td>
<td></td>
</tr>
<tr>
<td>Potassium Chloride Oral Tablets</td>
<td></td>
</tr>
<tr>
<td>Potassium Chloride Sustained Release Capsules</td>
<td></td>
</tr>
<tr>
<td>Potassium Chloride Sustained Release Tablets</td>
<td></td>
</tr>
<tr>
<td>Prazosin HCl</td>
<td></td>
</tr>
<tr>
<td>Primidone</td>
<td></td>
</tr>
<tr>
<td>Probuloc</td>
<td></td>
</tr>
<tr>
<td>Procanaimide HCl Capsules</td>
<td></td>
</tr>
<tr>
<td>Procyclidine</td>
<td></td>
</tr>
<tr>
<td>Propranolol HCl Tablets</td>
<td></td>
</tr>
<tr>
<td>Propranolol HCl Tablets</td>
<td></td>
</tr>
<tr>
<td>Propylthiouracil</td>
<td></td>
</tr>
<tr>
<td>Quinethazone Tablets</td>
<td></td>
</tr>
<tr>
<td>Quinidine Sulfate Tablets</td>
<td></td>
</tr>
<tr>
<td>Rauwolfia Serpentina Tablets</td>
<td></td>
</tr>
<tr>
<td>Reserpine and Trichloromethiazide</td>
<td></td>
</tr>
<tr>
<td>Reserpine Tablets</td>
<td></td>
</tr>
<tr>
<td>Sibronolactone</td>
<td></td>
</tr>
<tr>
<td>Syringes, Disposable, Insulin</td>
<td></td>
</tr>
<tr>
<td>Terazosin HCl</td>
<td></td>
</tr>
<tr>
<td>Terbutaline Sulfate</td>
<td></td>
</tr>
<tr>
<td>Theophylline</td>
<td></td>
</tr>
<tr>
<td>Theophylline Sustained Release Capsules</td>
<td></td>
</tr>
<tr>
<td>Theophylline Sustained Release Tablets</td>
<td></td>
</tr>
<tr>
<td>Thyroid Tablets</td>
<td></td>
</tr>
<tr>
<td>Timolol Maleate</td>
<td></td>
</tr>
<tr>
<td>Tolainide</td>
<td></td>
</tr>
<tr>
<td>Tolazamide Tablets</td>
<td></td>
</tr>
<tr>
<td>Tolbutamide</td>
<td></td>
</tr>
<tr>
<td>Triamcinolone Acetonide Oral Inhaler</td>
<td></td>
</tr>
<tr>
<td>Trichloromethiazide</td>
<td></td>
</tr>
<tr>
<td>Trihexyphenidyl</td>
<td></td>
</tr>
<tr>
<td>Valprao Acid</td>
<td></td>
</tr>
<tr>
<td>Valpoic Acid, E.C.</td>
<td></td>
</tr>
<tr>
<td>Verapamil HCl</td>
<td></td>
</tr>
<tr>
<td>Verapamil HCl Sustained Release Tablets</td>
<td></td>
</tr>
<tr>
<td>Warfarin Sodium Tablets</td>
<td></td>
</tr>
</tbody>
</table>


patients eligible for any of the fee-for-service programs.

PUBLISHER’S NOTE: The secretary of state has determined that the publication of the entire text of the material which is incorporated by reference as a portion of this rule would be unduly cumbersome or expensive. This material as incorporated by reference in this rule shall be maintained by the agency at its headquarters and shall be made available to the public for inspection and copying at no more than the actual cost of reproduction. This note applies only to the reference material. The entire text of the rule is printed here.

(1) The maximum days supply of medication which may be provided per dispensing on behalf of a patient eligible for any of the fee-for-service programs is thirty-one (31) day supply, except for those drugs and/or categories under the provisions of this rule. Medication may be dispensed in quantities less than a thirty-one (31) day supply, if so ordered by the prescriber, except as specified elsewhere in this rule.

(2) Drugs and/or categories of medications which are exempt from the thirty-one (31) day supply limitation and therefore may be dispensed in quantities exceeding a thirty-one (31) day supply are made available in the MO HealthNet Pharmacy Manual, section 13 CSR 70-20.050, Return of Drugs.

(3) All spend down recipients are exempt from the MO HealthNet thirty-one (31) day supply maximum restriction on pharmacy services.

(4) Exemptions from the thirty-one (31) day supply limitation may be given with prior authorization by the MO HealthNet Division to prevent a higher level of care.

(C) Indicate, as prescribed by the MO HealthNet Division, on each claim that the prescription was provided in packaging qualifying for the dispensing fee add-on to a participant in a long-term care facility.


13 CSR 70-20.070 Computer-Generated Drug Pricing Tape and Drug Reimbursement Methodology

PURPOSE: This rule establishes the basis and the method for pricing all drug claims in Missouri under the Title XIX Medicaid program. The purchase of a computer-generated tape, with weekly updates, will make it possible to utilize the computer for review purposes, which greatly increases the speed with which claims can be paid.

PUBLISHER’S NOTE: The publication of the full text of the material that the adopting agency has incorporated by reference in this rule would be unduly cumbersome or expensive. Therefore, the full text of that material will be made available to any interested person at both the Office of the Secretary of State and the office of the adopting agency, pursuant to section 536.031.4, RSMo. Such material will be provided at the cost established by state law.

(1) The Division of Medical Services will obtain, by contract with a reputable medical publishing company, a weekly computer-generated tape which will provide the information needed to price all fee-for-service Medicaid drug claims. The tape will contain National Drug Code (NDC), drug name, drug strength, dosage form, package size, the Average Wholesale Price (AWP), the prices set by direct-selling manufacturers (direct prices), Wholesaler Acquisition Cost (WAC), and federal Health and Human Services upper limits for specified multiple source drugs. A multiple source drug is defined as a drug marketed or sold by two (2) or more manufacturers or labelers, or a drug marketed or sold by the same manufacturer or labeler under two (2) or more different proprietary names or both under a proprietary name and without that name.

(2) The Division of Medical Services will add the Missouri Maximum Allowable Cost (MMAC) limits, for multiple source drugs as defined, to the data shown on the tape described in section (1) of this rule.

(3) Reimbursement for covered drugs will be made at the lower of the—
   (A) Usual and customary charge as billed by the provider; or
   (B) Price(s) included on the Drug Pricing File which is derived from one (1) or more of the following:
      1. The AWP as furnished by the state’s contracted agent, less ten and forty-three hundredths percent (10.43%);
      2. The MMAC as determined by the state agency for selected multiple source drugs;
      3. Applicable federal upper limits as found at www.dss.state.mo.us/dms; or
      4. The WAC as furnished by the state’s contracted agent, plus ten percent (10%).


13 CSR 70-20.071 Multiple Source Drugs for Which There Exists a Federal Upper Limit on Reimbursement

(Rescinded September 30, 2018)


13 CSR 70-20.080 Labeling of Medicaid Prescriptions

(Rescinded December 9, 1993)


13 CSR 70-20.100 Missouri Nonsteroidal Anti-Inflammatory Drug List

(Rescinded September 30, 1991)


13 CSR 70-20.110 Medicaid Program Coverage of Approved Drugs for Treatment of Acquired Immunodeficiency Syndrome (AIDS)

(Rescinded September 30, 1991)

13 CSR 70-20.120 Medicaid Program Coverage of Anti-Ulcer Preparations
(Rescinded June 29, 1989)


13 CSR 70-20.200 Drug Prior Authorization Process

PURPOSE: This rule establishes the division process by which drugs may be restricted under Section 4401 of P.L. 101-508 (Omnibus Budget Reconciliation Act of 1990) and are determined to be appropriate for inclusion as a regular benefit of the MO HealthNet program or through prior authorization.

(1) The following definitions shall be used in the interpretation and enforcement of this rule:

(A) “Clinical editing” shall be defined as that process which screens the use of specific medications on the basis of clinical appropriateness by requiring evidence of appropriate indications for use, and to achieve a cost savings, may require the initial use of less expensive agents.

(B) “Fiscal editing” shall be defined as a process that screens the use of specific medications to reimburse based on the least expensive dosage forms in order to achieve a cost savings.

(C) “Open access” shall be defined as the availability of a product without being subjected to prior authorization, clinical edits or step therapy but shall not preclude fiscal and utilization edits.

(D) “Preferred Drug List” shall be defined as a list of medications within a functional therapeutic class that are available via open access on the basis of supplemental rebate status and consideration of available evidence-based clinical review findings.

(E) “Step therapy” shall be defined as a process that specifies the sequence in which different prescription drugs are to be reimbursed.

(F) “Utilization edits” are defined as prospective screening edits used to review the appropriate use of medication and may be advisory or preemptory.

(2) This rule establishes a MO HealthNet Drug Prior Authorization Committee in the Department of Social Services, MO HealthNet Division. The committee shall be composed of three (3) practicing physicians licensed pursuant to Chapter 334, RSMo; three (3) practicing pharmacists licensed pursuant to Chapter 338, RSMo, one (1) of whom shall hold a doctoral degree in pharmacy (Pharm. D.); and one (1) registered professional nurse, as defined in Chapter 335, RSMo, practicing in a long-term care setting. All members shall be appointed by the director of the Department of Social Services. The members shall serve for a term of four (4) years. Members of the committee shall receive no compensation for their services, but shall be reimbursed for their actual and necessary expenses incurred, as approved by the MO HealthNet Division out of appropriations made for that purpose. The MO HealthNet Drug Prior Authorization Committee shall meet quarterly. The proposed dates for the meetings shall be announced for one (1) calendar year at the last meeting of the previous calendar year. If a meeting date is changed the new date must be posted at www.dss.mo.gov/mhd for at least thirty (30) days prior to the originally scheduled meeting.

(3) All persons eligible for medical assistance benefits shall have access to all pharmaceutical products for which there is federal financial participation except those drugs that may be restricted under Section 4401 of P.L. 101-508 (Omnibus Budget Reconciliation Act of 1990). The MO HealthNet Drug Prior Authorization Committee shall review those drugs that may be restricted and recommend those appropriate for inclusion as a regular benefit of the MO HealthNet program or through prior authorization.

(4) The department or the division may require prior authorization of pharmaceutical products. Any such restriction shall be based on medical and clinical criteria, and Missouri-specific data. The committee shall develop this medical and clinical criteria based on predetermined standards consistent with the following:

(A) The American Hospital Formulary Service Drug Information; and

(C) Peer-reviewed medical literature.

(5) If the division finds that the data enumerated in section (4) of this rule has been documented, the MO HealthNet Drug Prior Authorization Committee shall hold a public hearing prior to making recommendations to the department and prior to any final decision by the division to require prior authorization for that pharmaceutical product, class, or category.

(6) The tentative meeting agenda of the MO HealthNet Drug Prior Authorization Committee with the classes to be discussed shall be posted on the MO HealthNet Division website (www.dss.mo.gov/mhd) approximately fourteen (14) days prior to the meeting.

(A) Any interested party shall be granted the opportunity for clinically relevant public comment for up to fifteen (15) minutes in the aggregate per medication under review by the committee. The responsibility of scheduling the presentation shall rest with the manufacturer of the drug product.

(C) Following the consideration of all presented information, the committee shall make their final recommendation to the MO HealthNet Division by a majority vote of the members of the committee present thereto in a recorded roll call vote.

(D) The specific therapeutic class or classes recommended for restriction by means of step therapy, clinical edit, fiscal edit, or preferred drug list shall be available on the division website at www.dss.mo.gov/mhd approximately fifteen (15) calendar days after the meeting.

(7) The recommendations from the MO HealthNet Drug Prior Authorization Committee shall be referred to the Drug Utilization Review (DUR) Board for placement upon the agenda of the next regularly scheduled meeting. The DUR board may accept or alter the recommendations from the MO HealthNet Drug Prior Authorization Committee in arriving at their recommendation for the MO HealthNet Division. If provided to the division fourteen (14) days in advance of the DUR board meeting, clinically relevant written material shall be presented.
before the recommendation is considered by the DUR board. The DUR board, at their sole discretion, may entertain clinically relevant public comment up to fifteen (15) minutes in aggregate per medication. The responsibility of scheduling the presentation shall rest with the manufacturer of the drug product. Any changes recommended by the DUR board shall be made available via the approved minutes of the DUR board meeting in a timely fashion, at least thirty (30) days prior to the implementation of the recommendations.

(8) After all recommendations have been reviewed and accepted, the MO HealthNet Division staff shall coordinate the implementation of the recommendations. All pertinent information relating to edit schedule and edit criteria shall be made available to the public by reasonable means, including, but not limited to, posting on the division website in a timely fashion following the DUR board meeting. Changes to the MO HealthNet pharmacy benefit will be posted on a timely basis on the division website. In addition, information on covered medications shall be made available to the public for use with a personal digital assistant device. As determined by the division, patients stabilized on certain restricted medications shall be allowed to access such medication through the MO HealthNet program for as long as the MO HealthNet program determines that it is fiscally prudent and clinically supported.

(9) On an annual basis, the MO HealthNet Drug Prior Authorization Committee shall review all criteria in place, including prior authorization, step therapy, clinical edits, fiscal edits, and the preferred drug list. Annual reviews will be staggered and scheduled to occur at the scheduled meeting closest to completion of a full calendar year after approval of the criteria. If additional clinical or fiscal information is available since the original consideration, interested parties shall have the opportunity to address the committee and request reconsideration of prior authorization, step therapy, clinical edits, fiscal edits, and preferred drug list criteria. All requests shall be scheduled with the division fourteen (14) days in advance of the meeting. All such presentations shall be clinically relevant and limited to a maximum of fifteen (15) minutes. The responsibility of scheduling the presentation shall rest with the manufacturer of the drug product.

(10) The division shall not otherwise restrict the prescribing and dispensing of covered outpatient prescription drugs (other than Drug Efficacy Study Implementation (DESI) drugs as designated by federal law) pursuant to this rule without consulting the Drug Prior Authorization Committee. The division may limit the number of prescriptions allowed for each medical assistance participant.

(11) As used in the rule, DESI drugs are drugs described in section 107(c)(3) of the Drug Amendments of 1962 and identical, similar or related drugs (within the meaning of section 310.6(b)(1) of Title 21 of the Code of Federal Regulations).

(12) When implementing the provisions of section (4), Missouri-specific data shall include the consideration of use and cost data, pharmacoeconomic information and prudent utilization of state funds, and shall include medical and clinical criteria.


13 CSR 70-20.250 Prior Authorization of New Drug Entities or New Drug Dosage Form

**PURPOSE:** This rule outlines the process by which new drugs or new drug dosage forms of existing drugs may be subject to prior authorization prior to payment by Missouri’s medical assistance program.

(1) New drug entities, and new drug product dosage forms of existing drug entities, that have been approved by the Food and Drug Administration and are available on the market, shall comply with prior authorization requirements imposed by the division, in compliance with federal law.

(2) Prior authorization restrictions shall continue on new drug entities and new drug product dosage forms of existing drugs until reviewed by the division and the division eliminates the restriction or makes a final determination to require restriction. The division shall consider known cost and use data, medical and clinical criteria, and prudent utilization of state funds in the review. Interested parties may present clinical data to the division.

(3) The review referenced in section (2) shall occur within thirty (30) business days after the division receives notice through pricing updates of the availability of the drug entity on the market. Upon completion of the review, the division shall make the drug available for use by all MO HealthNet participants or refer the new drug or new drug dosage form to the MO HealthNet Drug Prior Authorization Committee (MDPAC) with a recommendation for continued prior authorization. Staff recommendations regarding continued prior authorization of a new drug or new drug dosage form shall be made in writing to the MDPAC. A copy shall be available to the public prior to the MDPAC meeting in which the continued prior authorization is to be discussed.

(4) The MDPAC shall consider any recommendations related to continued prior authorization of a new drug or new drug dosage form at the next scheduled MDPAC meeting. The division and the MDPAC may actively seek comments about the proposed restrictions. The MDPAC shall include a minimum of fifteen (15) minutes for any interested parties who have notified the division in advance of the scheduled meeting to comment about such proposed restrictions.

(5) If the MDPAC finds that use and cost data, pharmacoeconomic information, along with medical and clinical implications of restriction, are documented and restriction is warranted, the MDPAC shall hold a public hearing regarding the continued restriction and make a recommendation to the division. Such recommendation shall be provided to the division, in writing, prior to the division making a final determination. The division shall provide notice of the final determination through the Department of Social Services, MO HealthNet Division website at dss.state.mo.gov/mhd, provider bulletins, and updates to the provider manual.

(6) If, after the hearing referenced in section (5) above, prior authorization of the new drug or new drug dosage form is required, the prior authorization requirement shall be reviewed at least once every twelve (12) months by the MDPAC.

13 CSR 70-20.300 Retrospective Drug Use Review Process

PURPOSE: This rule establishes the division process by which the Drug Use Review Board will be established as required by Section 4401 of P.L. 101-508 (Omnibus Budget Reconciliation Act of 1990) and by section 208.175, RSMo.

(1) Drug Use Review (DUR) Board. This rule establishes a MO HealthNet DUR board in the Department of Social Services, MO HealthNet Division. The board shall be composed as specified in section 208.175, RSMo.

(2) Members of the DUR board must have the following minimum qualifications:

(A) Must be licensed by Missouri, with that license in active status and in good standing; and

(B) Must have recognized knowledge and expertise in one (1) or more of the following:

1. The clinically appropriate prescribing of covered outpatient drugs;
2. The clinically appropriate dispensing and monitoring of covered outpatient drugs;
3. Drug use review, evaluation, and intervention; or
4. Medical quality assurance.

(3) A chairperson shall be elected by the board members.

(4) The board shall meet at least once every ninety (90) days. A quorum of two-thirds (2/3) of the total members, including no fewer than two (2) physicians or two (2) pharmacists, is required for the board to act in its official capacity.

(5) Members shall serve four (4)-year terms, except the terms of the original members, two (2) shall be appointed for a term of two (2) years, three (3) shall be appointed for a term of three (3) years, and three (3) shall be appointed for a term of four (4) years. Members may be reappointed, provided that minimum qualifications for membership continue to be met. Nominations shall be referred for final appointment by the governor subject to advice and consent of the senate. As vacancies occur, the DUR board shall solicit and select a slate of nominees.

(6) The members of the board shall receive no compensation for their services other than reasonable expenses actually incurred in the performance of their official duties.

(7) The DUR board shall provide, either directly or through contracts between the MO HealthNet Division and accredited health care schools, state medical societies or state pharmacist associations or societies or other appropriate organizations, for educational outreach programs as required by P.L. 101-508, Section 4401, to educate practitioners on common drug therapy problems with the aim of improving prescribing and dispensing practices. This outreach shall include an educational newsletter to MO HealthNet providers including appropriate drug use guidelines and MO HealthNet utilization statistics.

(8) As specified by P.L. 101-508, Section 4401, the DUR board shall monitor drug use, and prescribing and dispensing practices in the MO HealthNet program. This monitoring shall include reviewing and refining therapeutic criteria modules used in both retrospective and prospective DUR, as well as overseeing retrospective DUR intervention methods used.

(9) The DUR board shall advise the Department of Social Services regarding all activities associated with the DUR process, including identifying types of intervention methods to be initiated by the review committees, ranging from letters to physicians and pharmacists, face-to-face education and educational symposiums for targeted providers. The board shall provide educational support and guidance as needed by the review committees. The review committees, in turn, shall report intervention results and make recommendations based on these results to the board.

(10) The DUR board shall review and research recommendations from the Drug Prior Authorization Committee, as established by 13 CSR 70-20.200, regarding the advisability of implementing or removing prior authorization requirements for a drug or class of drugs, and make a recommendation to the Department of Social Services.

(11) Specialized DUR Committees. Subject to appropriation, up to six (6) regional review committees may be appointed by the director of the Department of Social Services for the areas surrounding St. Louis, Kansas City, Springfield, Cape Girardeau, Kirksville and Columbia. Other specialized review committees may be formed at the discretion of the Department of Social Services. Members of the review committees shall be physicians and pharmacists appointed by the DUR board, totaling no fewer than five (5) and no more than ten (10) members per committee. A quorum of fifty-one percent (51%) of the total members must be present to conduct business. Regional committee members shall have the same minimum qualifications as required for the DUR board members. Regional committee meetings shall be held every other month. The members of each committee shall elect a chairperson, who shall serve as an ex officio member of the DUR board. Committee members shall receive no compensation other than reasonable expenses actually incurred in the performance of their official duties.

(12) The regional review committees shall conduct patient profile reviews, including opening and closing of cases at the committee meetings. Interventions shall be initiated and follow-up reviews performed by the regional committees. Patterns of inappropriate or aberrant prescribing or dispensing shall be identified and referred to the board in order for targeted education to be formulated.

(13) Agency Responsibility Regarding Confidentiality of Information. All information concerning applicants and MO HealthNet participants shall be confidential and any disclosure of this information shall be restricted to purposes directly related to the administration of the medical assistance program. Purposes directly related to administration of the medical assistance program include:

(A) Establishing eligibility;
(B) Determining the amount of medical assistance;
(C) Providing services for recipients; and
(D) Conducting or assisting an investigation, prosecution, or civil or criminal proceeding related to the administration of the program.

(14) Provider Responsibility Regarding Confidentiality of Information. All information concerning applicants and participants of medical services shall be confidential. Any disclosure of this information shall be restricted to purposes directly related to the treatment of the patient and promotion of improved quality of care. The confidential information includes:

(A) Names and addresses;
(B) Social Security number;
(C) Medical services provided;
(D) Social and economic conditions or circumstances;
(E) Medical data, including diagnosis and past history of disease or disability;
(F) Any information received for verifying income eligibility; and
13 CSR 70-20.310 Prospective Drug Use Review Process and Patient Counseling

PURPOSE: This rule establishes provisions for prospective drug use review and patient counseling for MO HealthNet beneficiaries, as required by Section 4401 or Public Law 101-508 (Omnibus Budget Reconciliation Act of 1990) and by section 208.176, RSMo.

(1) Prospective Drug Use Review (DUR). This rule establishes a MO HealthNet prospective drug use review process within the Department of Social Services, MO HealthNet Division, as specified in section 208.176, RSMo.

(2) Electronic Point-of-Sale Review. The MO HealthNet Division shall provide for electronic point-of-sale review of drug therapy using predetermined standards before each prescription is dispensed to the MO HealthNet participant or MO HealthNet participant’s caregiver for the current date of service. The process will provide screening for potential drug therapy problems using clinical modules which have been reviewed and approved for use by the Missouri Drug Use Review Board.

(3) Federal Prospective DUR screening requirements for MO HealthNet beneficiaries. 42 CFR part 456.705(b) requires that the state plan must provide for a point of distribution review of drug therapy using predetermined standards before each prescription is filled or delivered to the participant or the participant’s caregiver. The review, performed with or without online access to the pharmacy point of service system, must include screening to identify potential drug therapy problems of the following types:

(A) Incorrect drug dosage, that is, the dosage lies outside the daily dosage range specified in predetermined standards as necessary to achieve therapeutic benefit. Dosage range is the strength multiplied by the quantity dispensed divided by days supply;

(B) Adverse drug-drug interaction, that is, the potential for, or occurrence of, an adverse medical effect as a result of the participant using two (2) or more drugs together;

(C) Drug disease contraindication, that is the potential for, or occurrence of—

1. An undesirable alteration of the therapeutic effect of a given prescription because of the presence, in the patient for whom it is prescribed, of a disease condition;

(D) Therapeutic duplication, that is, the prescribing and dispensing of two (2) or more drugs from the same therapeutic class so that the combined daily dose puts the participant at risk of an adverse medical result or incurs additional program costs without additional therapeutic benefit;

(E) Incorrect duration of drug treatment, that is, the number of days of prescribed therapy exceeds or falls short of the recommendations contained in the predetermined standards;

(F) Drug allergy interactions, that is, the significant potential for, or occurrence of, an allergic reaction as a result of drug therapy;

(G) Clinical abuse/misuse, that is, the occurrence of situations referred to in the definitions of abuse, gross overuse, overutilization and underutilization, as defined in 42 CFR 456.702, and incorrect dosage and incorrect duration, as defined in subsections (3)(A) and (E) of this rule.

(4) Screens Available for MO HealthNet Beneficiaries. The following screens will be provided by the pharmacy point of service system:

(A) Drug Disease Contraindications.

1. Drug (actual) disease precaution.
2. Inferred Drug Disease precaution;

(B) Drug to Drug Interactions;

(C) Side Effects.

1. Additive toxicity side effects.
2. Medical condition/additive side effect.
3. Side effect.
4. Drug indicated for side effect of previously prescribed drug;

(D) Dose Range Checking.

1. High dose alert.
2. Low dose alert;

(E) Minimum/Maximum Daily Dose.

1. High dose alert.
2. Low dose alert;

(F) Duplicate Therapy Checking.

1. Therapeutic duplication.
2. Ingredient duplication; and

(G) Duration of Therapy (H2).

1. Excessive duration alert.

(5) MO HealthNet Patient Counseling. As part of the prospective DUR program, participating pharmacies shall perform patient counseling according to the standards established by the Board of Pharmacy under 20 CSR 2220-2.190.

(6) MO HealthNet Patient Profiles. The term, reasonable effort means that each time a MO HealthNet patient or caregiver presents a prescription, the pharmacist or pharmacist’s designee should request profile information verbally or in writing. For example, if the patient presents the prescription in person, the request should be made verbally, and if the prescription is received by mail, the request should be made in writing. This does not imply that the service should be denied solely on the basis of the patient’s refusal to supply this information. Pharmacies must make a reasonable effort to obtain records and maintain patient profiles containing, at a minimum:

(A) The name, address, telephone number, date of birth (or age), and gender of the patient;

(B) Individual medical history, if significant, including disease states, known allergies and drug reactions, and a comprehensive list of medications and relevant devices; and

(C) Pharmacist’s comments relevant to the individual’s drug therapy.

(7) Documentation of Offer to Counsel. The pharmacist shall document for each MO HealthNet patient’s prescription in a uniform fashion, whether the offer to counsel was accepted or refused by the patient or the patient’s agent.

(8) Agency Responsibility Regarding Confidentiality of Information. All information concerning applicants and participants of medical services shall be kept confidential by the MO HealthNet Division, and any disclosure of this information shall be restricted to purposes directly related to the administration of the medical assistance program. Purposes directly related to administration of the medical assistance program include:

(A) Establishing eligibility;

(B) Determining the amount of medical assistance;

(C) Providing services for participants; and

(D) Conducting or assisting an investigation, prosecution, or civil or criminal proceeding related to the administration of the program.

(9) Provider Responsibility Regarding Confidentiality of MO HealthNet Beneficiary Information. All information concerning
applicants and participants of medical services shall be confidential. Any disclosure of this information by the pharmacy provider shall be restricted to purposes directly related to the treatment of the patient and promotion of improved quality of care, or conducting or assisting an investigation, prosecution, or civil or criminal proceeding related to the administration of the program. The confidential information includes:

(A) Names and addresses;
(B) Social Security number;
(C) Medical services provided;
(D) Social and economic conditions or circumstances;
(E) Medical data, including diagnosis and past history of disease or disability;
(F) Any information received for verifying income eligibility; and
(G) Any information received in connection with the identification of legally liable third party resources.


13 CSR 70-20.320 Pharmacy Reimbursement Allowance

PURPOSE: This rule establishes a Pharmacy Federal Reimbursement Allowance and the methodologies to determine the formula for the amount of allowance each pharmacy is required to pay for the privilege of providing outpatient prescription drugs.

(1) Pharmacy Reimbursement Allowance (PRA). PRA shall be assessed as described in this section.

(A) Definitions.
1. Department—Department of Social Services.
2. Director—Director of Department of Social Services.
3. Division—MO HealthNet Division.
4. Gross retail prescription receipts—For ease of administration for the department as well as the industry, this shall be an annual amount. The basis of tax in any fiscal year will be the gross prescription sales of the last calendar year prior to the previous fiscal year.
5. Each pharmacy engaging in the business of providing outpatient prescription drugs in Missouri to the general public shall pay a PRA.

1. The PRA owed for existing pharmacies shall be calculated by multiplying the pharmacy’s total gross retail prescription receipts by the tax rate determined by the department. Subject to the limitations established in section 338.520, RSMo, such said tax rate shall be uniform and shall not exceed five percent (5%).
2. The PRA shall be divided by and collected over the number of months for which the PRA is effective.
3. The initial PRA owed by a newly licensed pharmacy shall be calculated by estimating the total prescription sales and multiplying the estimate by the rate determined by the department, as described in paragraph (1)(B)1.
4. If a pharmacy ceases to provide outpatient prescription drugs to the general public, the pharmacy is not required to pay the PRA during the time it did not provide outpatient prescription drugs.
5. If the pharmacy reopens, it shall resume paying the PRA. It shall owe the same PRA as it did prior to closing, if the PRA has not changed per paragraph (1)(B)1.

(C) Each pharmacy shall submit an affidavit to the department with the following information:
1. Pharmacy name;
2. Contact;
3. Telephone number;
4. Address;
5. Federal tax ID number;
6. MO HealthNet pharmacy number (if applicable);
7. Pharmacy sales (total);
8. MO HealthNet pharmacy sales;
9. Number of paid MO HealthNet prescriptions; and
10. Gross receipts attributable to prescription drugs that are delivered directly to the patient via common carrier, by mail, or a courier service.

(D) The department shall prepare a confirmation schedule of the information provided by each pharmacy and the amount of PRA that is due from the pharmacy.

(E) Each pharmacy shall review the information prepared by the department and the amount of PRA calculated by the department to verify that the information is correct.
1. If the information supplied by the department is incorrect, the facility, within thirty (30) calendar days of receiving the confirmation schedule must notify the division and explain the correction.
2. If the division does not receive corrected information within thirty (30) calendar days, it will be assumed to be correct, unless the pharmacy files a protest in accordance with subsection (2)(D) of this regulation.

(2) Payment of the PRA.

(A) Offset.
1. Each pharmacy may request that its PRA offset against any MO HealthNet payment due to that pharmacy.
2. A statement authorizing the offset must be on file with the division before any offset may be made relative to the PRA by the pharmacy.
3. Assessments shall be allocated and deducted over the applicable service period.
4. Any balance due after the offset shall be remitted to the director of the Department of Revenue and be deposited in the state treasury to the credit of the Pharmacy Reimbursement Allowance Fund.
5. If the remittance is not received before the next MO HealthNet payment cycle, the division shall offset the balance due from that check.
6. Check.
1. If no offset has been authorized by the pharmacy, the division will begin collecting the pharmacy reimbursement allowance on the first day of each month for the preceding months.
2. The PRA shall be remitted by the pharmacy to the department. The remittance shall be made payable to the director of the Department of Revenue and be deposited in the state treasury to the credit of the Pharmacy Reimbursement Allowance Fund.
3. Failure to comply with this request for information or failure to pay the PRA.
1. If a pharmacy fails to comply with a request for information from the MO HealthNet Division or fails to pay its PRA within thirty (30) days of notice, the PRA shall be delinquent.
2. For any delinquent PRA, the department may:
   A. Proceed to enforce the state’s lien of the property of the pharmacy;
   B. Cancel or refuse to issue, extend, or reinstate the MO HealthNet provider agreement; or
   C. Seek denial, suspension, or revocation of license granted under Chapter 338, RSMo.
3. The new owner, as a result of a change in ownership, shall have his/her PRA paid by the same method the previous owner elected.
4. Each pharmacy, upon receiving written notice of the final determination of its PRA, may file a protest with the director of the department setting forth the grounds on which the protest is based, within thirty (30) days from the date of receipt of written notice from the department. The director of the department shall reconsider the determination and, if the pharmacy so requested, grant
performed medication therapy management services by qualified professional persons who may hold the qualification as a pharmacist or pharmacy technician as provided in section 338.505, RSMo 2002.

PURPOSE: This rule establishes the regulatory basis for the administration of the MO HealthNet Medication Therapy Management (MTM) program, including designation of professional persons who may perform medication therapy management services and defined covered services within the program.

PUBLISHER’S NOTE: The secretary of state has determined that the publication of the entire text of the material which is incorporated by reference as a portion of this rule would be unduly cumbersome or expensive. This material as incorporated by reference in this rule shall be maintained by the agency at its headquarters and shall be made available to the public for inspection and copying at no more than the actual cost of reproduction. This note applies only to the reference material. The entire text of the rule is printed here.

1. The PRA tax rate will be a uniform effective rate of one and twenty-hundredths percent (1.20%) with an aggregate quarterly adjustment, by the MO HealthNet Division, not to exceed five hundredths percent (0.05%) based on the pharmacy’s total prescription volume.

2. Beginning January 1, 2010, the PRA tax rate will be a uniform effective rate of one and eighty-two hundredths percent (1.82%) with an aggregate quarterly adjustment, by the MO HealthNet Division, not to exceed five tenths percent (0.5%) based on the pharmacy’s total prescription volume.

3. The maximum rate shall be five percent (5%).


13 CSR 70-20—DEPARTMENT OF SOCIAL SERVICES Division 70—MO HealthNet Division

13 CSR 70-20.330 Medication Therapy Management (MTM) Program

PURPOSE: This rule establishes the regulatory basis for the administration of the MO HealthNet Medication Therapy Management (MTM) program, including designation of professional persons who may perform medication therapy management services and defined covered services within the program.

1. Administration. The Medication Therapy Management (MTM) program shall be administered by the Department of Social Services, MO HealthNet Division. The MTM services covered, the program limitations, and the maximum allowable fees for all covered services shall be determined by the Department of Social Services, MO HealthNet Division, and shall be included in the pharmacy provider manual and provider bulletins, which are incorporated by reference and made a part of this rule as published by the Department of Social Services, MO HealthNet Division, 615 Howerton Court, Jefferson City, MO 65109, at its website at dss.mo.gov/mhd/index.htm, September 1, 2015. This rule does not incorporate any subsequent amendments or additions.

2. Persons Eligible. A person who is eligible for Title XIX (Medicaid) or Title XXI (State Children’s Health Insurance Program) or Blind Pension and who meets certain disease-based criteria included in their health profile.

3. Provider Participation. To be eligible for participation in the MO HealthNet MTM program, a provider must be a qualified Missouri licensed pharmacist and have an active MO HealthNet provider status, and must have successfully completed two (2) hours of ACPE (Accreditation Counsel for Pharmacy Education) accredited continuing education focused on the administration of MTM approved by the MO HealthNet Division.

4. Medication Therapy Management Services. MTM Services are available to any currently eligible non-managed care MO HealthNet participant for whom the qualifying pharmacist receives a MO HealthNet directed electronic drug utilization review (DUR) message through a Point-of-Sale transaction. MO HealthNet uses a clinically based rules engine that juries which participants require MTM interventions based on nationally accepted evidence-based guidelines. Pharmacists are then messaged about only those participants who are identified for one (1) or more issues pertinent to the evidence-based criteria. The rules engine uses current nationally accepted evidence-based guidelines for clinically appropriate drug therapy, and applies this criteria to thirty-six (36) months of paid participant claims data which includes drugs, diagnoses, and procedures. When an eligible participant meets certain disease-based criteria a pharmacist may perform a wide variety of MTM services directed by MO HealthNet to address specific treatment needs, such as:

(A) Counseling participants on the importance of medication adherence (alerting participants to missed dosages and refills);
(B) Providing medication education;
(C) Providing self-care education for specific chronic conditions;
(D) Contacting physician to schedule diagnostic testing;
(E) Contacting physicians to make drug therapy recommendations; or
(F) Connecting participants with other community-based resources as needed.

5. The service is comprised of the following components:

(A) Assessing a participant’s health status;
(B) Developing a medication treatment plan;
(C) Monitoring and evaluating a participant’s response to therapy;
(D) Providing a comprehensive medication review to identify, resolve, and prevent medication-related problems;
(E) Documenting the care provided and communicating essential information to a participant’s primary care providers;
(F) Providing oral education and training to enhance participant understanding and appropriate use of medications;
(G) Providing information, support services, and resources to enhance participant adherence to therapeutic regimens; and
(H) Coordinating and integrating MTM services within the broader health care services provided to a participant.

6. Reimbursement. Pharmacists will receive the payment for participating in MTM. The payment is contingent upon the provider logging on to the electronic web tool to view, reserve, and complete interventions. Once an intervention is complete, providers will submit an electronic medical claim to MO HealthNet. The payment status of these claims will be reflected on the provider’s remittance advice. The fee schedule is available at dss.mo.gov/mhd/providers/pages/cptagree.htm.
13 CSR 70-20.340 National Drug Code Requirement

PURPOSE: This rule implements the requirement for the National Drug Code (NDC) for all medications administered in the clinic or outpatient hospital setting. The Deficit Reduction Act of 2005 (DRA) requires states to collect rebates for certain physician-administered drugs.

(1) Claims from 340B health care facilities for outpatient hospital covered are exempt from the NDC requirement in this rule so long as those claims utilize a valid J-Code (not a dump code) and comply with all other applicable state and federal laws.

(2) All drug products produced by manufacturers that have entered into a rebate agreement with the Federal Government are reimbursable under the MHD Pharmacy Program, with the exception of Drug Efficacy Study Implementation (DESI) drugs and drugs specified in Section 13, "Benefits and Limitations," in the Pharmacy Manual. The MHD Pharmacy Manual can be found on the MHD website at: http://manuals.mommed.com/collections/collection_pharmacy/print.pdf. A list of manufacturers that have entered into a rebate agreement with the Federal Government (along with the Labeler Code which is the first five (5) digits of the NDC number by which products may also be identified), can be found on the Centers for Medicare and Medicaid Services (CMS) website, in Drug Manufacturer Contact Information at: http://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Medicaid-Drug-Rebate-Program.html. Products for which the Labeler Code is not included on the list are not reimbursable under the MHD Pharmacy Program.

(3) Drug charges submitted by providers on an electronic Professional or Institutional ASC X12 837 Health Care claim transaction or manually entered on a medical or outpatient claim into MHD’s billing website eMOMED (www.emomed.com), are to be billed with a valid J-Code and a valid NDC for each medication, including injections, provided to the participant. Medical or outpatient claim lines submitted with a J-Code without the corresponding NDC will be denied. For medical or outpatient claims correctly submitted with the appropriate J-Code and the corresponding NDC, the system will automatically generate a separate drug claim for the NDC to process as a pharmacy claim and will appear as a separate claim on your Remittance Advice. The corresponding line with J-Code and NDC will be dropped from the medical or outpatient claim. If an NDC is not provided, the J-Code will remain on the claim to report the denied line. If the drug being provided does not have a J-Code associated with it, the appropriate Healthcare Common Procedure Coding System (HCPCS) procedure code should be submitted with an NDC. For drugs without a valid HCPCS procedure code, revenue code 0250 “General Classification: Pharmacy” must be used with the appropriate NDC. Only drugs and items used during outpatient care in the hospital are covered. Take-home medications and supplies are not covered by MHD under the Hospital Program.

(4) A critical component to submitting claims with an NDC is to ensure that the appropriate HCPCS procedure code is billed with each NDC. To ensure accurate billing of drug charges, MHD will use the Noridian Crosswalk (www.dmempad.com) to determine whether the appropriate HCPCS procedure code is billed for the submitted NDC. Claims will be denied if the NDC submitted is not valid for the HCPCS procedure code submitted.

(5) Effective for dates of service on or after April 1, 2016, MO HealthNet Division (MHD) will require the National Drug Code (NDC) for all medications administered in the clinic or outpatient hospital setting, to comply with federal law. MHD must collect the eleven- (11-) digit NDC on all outpatient drug claims submitted to MHD from all providers for rebate purposes in order to receive federal financial participation. Providers will be required to submit their claims with the exact NDC that appears on the product dispensed, rather than per dose. MHD paid claim history.

(6) All drug claims shall be routed through an automated computer system to apply edits specifically designed to ensure effective drug utilization. The Preferred Drug List (PDL) and clinical edits are designed to enhance patient care and optimize the use of program funds through therapeutically prudent use of pharmaceuticals. The edits are based on evidence-based clinical criteria and nationally recognized peer-reviewed information. This clinical information is paired with fiscal evaluation and then developed into a therapeutic class PDL recommendation. The PDL process incorporates clinical edits, including step therapies, into the MHD pharmacy program. Claims for drugs will automatically and transparently be approved for those patients who meet any of the system approval criteria. For those patients who do not meet the system approval criteria, the drugs will require a call to the MHD Drug Prior Authorization hotline at (800) 392-8030 to initiate a review and potentially authorize payment of claims. Providers may also use the CyberAccess tool to prospectively determine if a drug is a preferred agent and requires edit override, electronically initiate an edit override review, and to review a participant’s MHD paid claim history.

(7) The quantity to be billed for injectables and other types of medications dispensed to MHD participants must be calculated as follows:

(A) Containers of medication in solution (for example, ampoules, bags, bottles, vials, syringes) must be billed by exact cubic centimeters or milliliters (cc or mL) dispensed, even if the quantity includes a decimal (e.g., if three (3) 0.5 mL vials are dispensed, the correct quantity to bill is 1.5 mL);

(B) Single dose syringes and single dose vials must be billed per cubic centimeters or milliliters (cc or mL), rather than per syringe or per vial;

(C) Ointments must be billed per number of grams even if the quantity includes a decimal;

(D) Eye drops must be billed per number of cubic centimeters or milliliters (cc or mL) in each bottle even if the quantity includes a decimal;

(E) Powder filled vials and syringes that require reconstitution must be billed by the number of vials;

(F) Combination products, which consist of devices and drugs, designed to be used together, are to be billed as a kit. Quantity will be the number of kits used;

(G) The product Herceptin, by Genentech, must be billed by milligram rather than by vial due to the stability of the drug; and

(H) Non-Vaccines for Children (VFC) Immunizations and vaccines must be billed by the cubic centimeters or milliliters (cc or mL) dispensed, rather than per dose.
(8) Contrast materials and radiopharmaceuticals used in radiologic procedures may be billed separately using the appropriate HCPCS code and/or the NDC representing the materials or agent used in the procedure. If available, MHD would prefer the NDC for reporting purposes. If the material or agent used does not have an NDC, the appropriate HCPCS code alone is acceptable. All HCPCS codes for contrast materials and radiopharmaceuticals are manually priced and must be billed with the manufacturer’s invoice of cost attached to the claim.
